Journal: | Revista de investigación clínica |
Database: | PERIÓDICA |
System number: | 000389657 |
ISSN: | 0034-8376 |
Authors: | Demichelis Gómez, Roberta1 Crespo Solís, Erick1 Pérez Jacobo, Luis Fernando1 Valencia Rocha, Ubaldo Rafael1 Rosas López, Adriana1 |
Institutions: | 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Hematología y Oncología, Tlalpan, Distrito Federal. México |
Year: | 2015 |
Season: | Sep-Oct |
Volumen: | 67 |
Number: | 5 |
Pages: | 287-295 |
Country: | México |
Language: | Inglés |
Document type: | Artículo |
Approach: | Experimental, caso clínico |
English abstract | Treatment of relapsed/refractory acute myeloid or lymphoid leukemia consists of salvage chemotherapy followed by allogeneic hematopoietic stem-cell transplantation. Intravenous fludarabine, cytarabine, and filgrastim is an effective regimen in this setting. In view of the lack of availability of intravenous fludarabine in Mexico from 2009-2013, we substituted an equivalent oral fludarabine dose (40 mg) for the intravenous formulation. Objective: This is a retrospective comparison of the toxicity and effectiveness of oral fludarabine, cytarabine, and filgrastim versus intravenous fludarabine, cytarabine and filgrastim. Results: A total of 44 patients with relapsed/refractory acute myeloid leukemia or acute lymphoid leukemia treated in an academic medical center from 2005-2013 with oral fludarabine, cytarabine and filgrastim (21 patients) or intravenous fludarabine, cytarabine and filgrastim (23 patients) were included in the analysis. There was a trend towards a higher complete remission rate and a longer overall survival following intravenous fludarabine, cytarabine, and filgrastim as compared with oral fludarabine, cytarabine, and filgrastim: complete remission rates 39.1 vs. 23.8% (p = 0.342) and overall survival 6.14 vs. 10.78 months (p = 0.363), respectively. A higher incidence of neutropenic fever (100 vs. 76.2%; p = 0.019) and septic shock (34.8 vs. 0%; p = 0.003) and a longer hospitalization (26.8 vs. 19.4 days; p = 0.046) were observed with intravenous fludarabine, cytarabine, and filgrastim. In multivariate analysis, factors associated with a shorter survival were septic shock (HR: 3.93; 95% CI: 1.67-9.25; p = 0.002) and a higher number of previous treatments (HR: 2.5; 95% CI: 1.26-4.99; p = 0.009). Complete remission was associated with better survival (HR: 0.18; 95% CI: 0.08-0.44; p < 0.001). Conclusions: Further studies are needed to determine the optimal dose and timing of oral fludarabine, cytarabine and filgrastim |
Disciplines: | Medicina |
Keyword: | Farmacología, Oncología, Fludarabina, Leucemia aguda, Recurrencia, Citarabina |
Keyword: | Medicine, Oncology, Pharmacology, Fludarabine, Acute leukemia, Recurrence, Cytarabine |
Full text: | Texto completo (Ver PDF) |